Loading...
XNASOCGN
Market cap229mUSD
Jan 10, Last price  
0.79USD
1D
-5.33%
1Q
-20.14%
Jan 2017
-52.90%
IPO
-92.91%
Name

Ocugen Inc

Chart & Performance

D1W1MN
XNAS:OCGN chart
P/E
—
P/S
37.96
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
230.65%
Rev. gr., 5y
%
Revenues
6m
+142.60%
26,0008,00000000042,62002,488,0006,036,000
Net income
-63m
L-18.96%
-16,935,000-25,712,000-22,793,000-32,024,000-16,208,000-26,414,000-8,643,000-21,225,593-22,623,468-58,365,000-77,834,000-63,078,000
CFO
-62m
L+3.29%
-12,232,000-15,282,000-18,405,000-30,034,000-25,736,000-23,020,000-15,777,000-16,893,281-14,708,730-47,941,000-60,079,000-62,054,000
Earnings
Mar 31, 2025

Profile

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
URL
https://ocugen.com/
IPO date
Dec 03, 2014
Employees
84
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,036
142.60%
2,488
 
Cost of revenue
72,271
85,941
Unusual Expense (Income)
NOPBT
(66,235)
(83,453)
NOPBT Margin
Operating Taxes
(3,997)
Tax Rate
NOPAT
(66,235)
(79,456)
Net income
(63,078)
-18.96%
(77,834)
33.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
20,804
59,567
BB yield
-14.81%
-21.35%
Debt
Debt current
1,148
498
Long-term debt
10,508
9,961
Deferred revenue
(975)
Other long-term liabilities
527
244
Net debt
(27,806)
(80,475)
Cash flow
Cash from operating activities
(62,054)
(60,079)
CAPEX
(10,476)
(4,457)
Cash from investing activities
3,077
(16,967)
Cash from financing activities
20,881
59,475
FCF
(77,472)
(83,294)
Balance
Cash
39,462
90,934
Long term investments
Excess cash
39,160
90,810
Stockholders' equity
(283,579)
(210,774)
Invested Capital
332,185
300,469
ROIC
ROCE
EV
Common stock shares outstanding
244,327
214,600
Price
0.58
-55.77%
1.30
-71.43%
Market cap
140,488
-49.64%
278,980
-68.56%
EV
112,683
198,506
EBITDA
(65,531)
(82,973)
EV/EBITDA
Interest
3,517
Interest/NOPBT